There are currently 827 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2025
Locations: Community Cancer Center East, Indianapolis, Indiana +2 locations
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Interventional Study Exploring the Occurrence of Surgical Site Infections.
NCT06661473
Recruiting
Interventional study exploring surgical site complication occurrences in high-risk revision patients undergoing TKA or THA using NPWT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Ortho Indy, Indianapolis, Indiana
Conditions: Total Knee Arthroplasty, Total Hip Arthroplasty Revision, Total Knee Arthroplasty Revision
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Franciscan Physician Network, Indianapolis, Indiana +1 locations
Conditions: Heart Failure
Register for Updates
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
NCT05197920
Recruiting
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Acute Pancreatitis
Register for Updates
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: Indiana University IU Health Neuroscience Center, Indianapolis, Indiana
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Community Health Network, Indianapolis, Indiana
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
NCT05022459
Recruiting
Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive damage that affects mobility and quality of life. Prophylactic FVIII administered intravenously every other day has been the standard of care treatment for HA for the past few decades. Sports and phys... Read More
Gender:
MALE
Ages:
Between 6 years and 19 years
Trial Updated:
05/05/2025
Locations: Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana
Conditions: Hemophilia A
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Indiana University Hospital/Riley Hospital for Children, Indianapolis, Indiana
Conditions: Severe Aplastic Anemia
Register for Updates
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
NCT06593652
Recruiting
Intervention for mild severity alcohol use among U.S. teens is crucial, as alcohol is the most commonly used substance in this age group, yet few receive the necessary interventions. Primary care, where over 90% of youth regularly visit, is an ideal setting for identifying and addressing mild alcohol use disorder (AUD) through brief interventions like motivational interviewing (MI) and cognitive-behavioral therapy (CBT). However, for teens with mild AUD, a single brief session may not be suffici... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/02/2025
Locations: IU Health/Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Alcohol Use, Adolescent, Mild Alcohol Use Disorder, Mild Substance Use Disorder
Register for Updates
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
NCT04323046
Recruiting
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
05/02/2025
Locations: Riley Children's Hospital, Indianapolis, Indiana
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Register for Updates
Robotic Gait Rehabilitation in Parkinson's Disease
NCT05218187
Recruiting
The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes. Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: IU Health Neurorehabilitation and Robotics, Indianapolis, Indiana
Conditions: Parkinson Disease, Gait Disorder, Sensorimotor
Register for Updates
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523
Recruiting
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/02/2025
Locations: Ascendis Investigational Site, Indianapolis, Indiana
Conditions: Growth Hormone Deficiency
Register for Updates